Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC +12.50%27 Equity-to-Asset is 0.82 as of Dec. 2025, which is 32% above its 10-year median of 0.62. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, CytoMed Therapeutics ranks better than 69.3% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CytoMed Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $5.07 Mil. CytoMed Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $6.19 Mil.
Therefore, CytoMed Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.82.
The historical rank and industry rank for CytoMed Therapeutics's Equity-to-Asset or its related term are showing as below:
GDTC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.62 Max: 0.91
Current: 0.82
During the past 6 years, the highest Equity to Asset Ratio of CytoMed Therapeutics was 0.91. The lowest was 0.11. And the median was 0.62.
GDTC's Equity-to-Asset is ranked better than 69.3% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs GDTC: 0.82
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CytoMed Therapeutics Equity-to-Asset Related Terms
CytoMed Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GDTC vs LEXX, INAB, TRAW: Equity-to-Asset Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CytoMed Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics (GDTC) has a Equity-to-Asset of 0.82 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CytoMed Therapeutics and its competitors. This is 32% above median its historical median of 0.62. Over the past decade, CytoMed Therapeutics' Equity-to-Asset has ranged from 0.11 to 0.91. According to the industry distribution chart, CytoMed Therapeutics ranks #435 out of 1417 companies in the Biotechnology industry, placing it in the top 30.7%.
Is CytoMed Therapeutics' Equity-to-Asset too high?
CytoMed Therapeutics' current Equity-to-Asset of 0.82 is 32% above median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.91. The Biotechnology industry median Equity-to-Asset is 0.68. CytoMed Therapeutics' value of 0.82 is 20.6% above this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #435 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Equity-to-Asset compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #435 out of 1417 companies for Equity-to-Asset. This puts CytoMed Therapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. CytoMed Therapeutics' value of 0.82 is 20.6% above this benchmark. Historically, CytoMed Therapeutics' own Equity-to-Asset has ranged from 0.11 to 0.91 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.68, CytoMed Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current Equity-to-Asset of 0.82 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current Equity-to-Asset is 0.82, which is 32% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current Equity-to-Asset of 0.82. The current Equity-to-Asset is 0.82, which is 32% above median its 10-year median of 0.62 and 20.6% above the Biotechnology industry median of 0.68. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current Equity-to-Asset is 0.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
